Table 2 Risk of outcomes exposed to Paxlovid compared to non-Paxlovid
Paxlovid | Non-Paxlovid | ||||
|---|---|---|---|---|---|
N | No. of event | N | No. of event | HR | |
Use Paxlovid within the first day of a diagnosed COVID-19 infection | |||||
Cerebrovascular complications | 7190 | 49 | 7190 | 117 | 0.57 (0.40–0.79) |
Arrhythmia | 7190 | 172 | 7190 | 321 | 0.73 (0.60–0.87) |
Inflammatory heart disease | 7190 | 10 | 7190 | 23 | 0.41 (0.17–0.97) |
Ischemic heart disease | 7190 | 24 | 7190 | 57 | 0.61 (0.37–0.99) |
Other cardiac disorders | 7190 | 30 | 7190 | 77 | 0.51 (0.33–0.77) |
Thrombotic disorders | 7190 | 26 | 7190 | 73 | 0.48 (0.30–0.75) |
Major adverse cardiac events | 7190 | 84 | 7190 | 197 | 0.60 (0.46–0.77) |
Any cardiovascular outcome mentioned above | 7190 | 261 | 7190 | 519 | 0.67 (0.57–0.78) |
Mortality | 7190 | 10 | 7190 | 46 | 0.20 (0.09–0.45) |
Admission | 7190 | 369 | 7190 | 690 | 0.70 (0.61–0.79) |
ICU | 7190 | 17 | 7190 | 58 | 0.41 (0.23–0.71) |
Use Paxlovid within days 2 to 5 of a diagnosed COVID-19 infection | |||||
Cerebrovascular complications | 407 | 10 | 407 | 12 | 0.44 (0.15–1.24) |
Arrhythmia | 407 | 12 | 407 | 28 | 0.46 (0.23–0.91) |
Inflammatory heart disease | 407 | 10 | 407 | 10 | 0.66 (0.05–7.57) |
Ischemic heart disease | 407 | 10 | 407 | 10 | 0.36 (0.07–1.72) |
Other cardiac disorders | 407 | 10 | 407 | 10 | 0.42 (0.11–1.57) |
Thrombotic disorders | 407 | 10 | 407 | 10 | 0.46 (0.11–1.78) |
Major adverse cardiac events | 407 | 10 | 407 | 19 | 0.34 (0.13–0.85) |
Any cardiovascular outcome mentioned above | 407 | 20 | 407 | 48 | 0.44 (0.26–0.74) |
Mortality | 407 | 10 | 407 | 10 | 0.15 (0.01–1.19) |
Admission | 407 | 35 | 407 | 39 | 1.00 (0.63–1.58) |
ICU | 407 | 10 | 407 | 10 | 0.32 (0.06–1.55) |